AstraZeneca Pharma India surges on getting CDSCO’s nod to import, distribute Durvalumab solutions
Astrazeneca Pharma India is currently trading at Rs. 7050.00, up by 210.35 points or 3.08% from its previous closing of Rs. 6839.65 on the BSE.
The scrip opened at Rs. 6900.00 and has touched a high and low of Rs. 7099.60 and Rs. 6762.90 respectively. So far 390 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 8139.85 on 30-Sep-2024 and a 52 week low of Rs. 4050.15 on 21-Mar-2024.
Last one week high and low of the scrip stood at Rs. 7154.50 and Rs. 6609.60 respectively. The current market cap of the company is Rs. 17625.13 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 8.14% and 16.87% respectively.
AstraZeneca Pharma India has received approval from drug regulator - Central Drugs Standard Control Organisation (CDSCO) to import and distribute cancer treatment medicine Durvalumab solutions in the country. The approval by CDSCO, Directorate General of Health Services, Government of India is for import, for sale and distribution of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) for an additional indication.
Durvalumab in combination with Tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC). The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
